Why scientists don’t back Novartis claim
As Novartis’ Indian patent case reaches end, a reminder of how scientists view unfair patents
Menacing US diplomacy
Specialist attachés are strenuously pushing maximalist intellectual property rules worldwide
WHOSE SEED IS IT ANYWAY?
The rich world’s mania for patenting seeds and pushing the UPOV agenda do not aid food security or biological diversity
Blacked out & hacked
The fight to protect Internet freedom turns into war of attrition as protests against US measures to curb piracy grow strident
Acta is trade terrorism
India’s generic medicines export faces a huge threat from the anti-counterfeiting law which creates barriers to global trade
Coronavirus vaccines: TRIPS waiver caught in WTO labyrinth
Little change in the position of countries opposing waiver of intellectual property rights; India-South Africa proposal being through hoops …
Ignore US bullying on IPRs
Countries should not be stampeded into changing laws by the USTR's arbitrary Special 301 report
The innovation WHO needs
The strategy to push public health, innovation and intellectual property is a tough challenge because of funding constraints
FARM IP, ENTER WIPO
Developing countries will now have to battle IP issues related to new agricultural technologies at WIPO instead of WTO
Brickbats for compulsory licences
US criticises India and BRIC group for strengthening provisions on life-saving medicines
Crazy for GI? Think again
The protection of Geographical Indication is not a guarantee that the artisan or producer will benefit; traders can corner the premium
A rather ridiculous gap
Clothing giant Gap’s trademark infringement notice to an NGO selling products made from recycled waste is a curious case
The fine line for judges
Judges have recused themselves in a number of cases but there are no clear guidelines on what constitutes conflict of interest
NCD battle starts now
The UN agreement on non-communicable diseases will get snagged on the issue of intellectual property rights for drugs
Obama takes first dip
The US becomes the first to join a global patents pool to make AIDS drugs cheaper but health workers are sceptical of the initiative
Access, yes. Sharing, no
The access and benefit-sharing protocol on biodiversity may do little to deter multinationals from grabbing the planet’s resources
European Parliament rejects Anti-Counterfeiting Trade Agreement
Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries
Act of omission
Public institutions do not seek permission from the biodiversity authority before genetically manipulating crops
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
It’s still open season for bio-piracy
Rich nations block accord on benefit-sharing rules for the world’s genetic resources
Gunning for green tech
US continues to target India over its intellectual property regime, especially in pharma, green tech sectors
Choking access to drugs
Drug prices are likely to increase as rich countries and their pharma companies squeeze Indian generics out of the market. How can India’s …
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …